Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck’s Januvia/Metformin Combo To Be Branded Janumet

This article was originally published in The Pink Sheet Daily

Executive Summary

The sitagliptin fixed-dose combination therapy, formerly known as MK-0431A, has a late March user fee date.

You may also be interested in...



Skin Toxicity Seen In Other DPP-4 Inhibitors Missing In Januvia NDA – FDA Review

FDA’s request for additional primate studies to assess potential skin toxicity stemmed from findings with other agents of the same class, agency review documents show.

Skin Toxicity Seen In Other DPP-4 Inhibitors Missing In Januvia NDA – FDA Review

FDA’s request for additional primate studies to assess potential skin toxicity stemmed from findings with other agents of the same class, agency review documents show.

Bristol-Myers Squibb Latest To License DPP-4 Patents From OSI

OSI "owns the patent estate" on DPP-4 inhibitors and has licensed the medical use patents to Merck, Novartis and others.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS063507

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel